Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Arcturus Therapeutics Holdings 14-Day RSI Related Terms
ARCT vs MDWD, UNCY, EQ: 14-Day RSI Comparison
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcturus Therapeutics Holdings 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings (ARCT) has a 14-Day RSI of 31.92 as of Jul. 19, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Arcturus Therapeutics Holdings and its competitors. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #107 out of 1425 companies in the Biotechnology industry, placing it in the top 7.5%.
Is Arcturus Therapeutics Holdings' 14-Day RSI too high?
Arcturus Therapeutics Holdings' current 14-Day RSI is 31.92. The Biotechnology industry median 14-Day RSI is 45.58. Arcturus Therapeutics Holdings' value of 31.92 is 30% below this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #107 out of 1425 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' 14-Day RSI compare to MDWD and UNCY?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #107 out of 1425 companies for 14-Day RSI. This places Arcturus Therapeutics Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 45.58. Arcturus Therapeutics Holdings' value of 31.92 is 30% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.58, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current 14-Day RSI of 31.92 is 30% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Arcturus Therapeutics Holdings and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current 14-Day RSI is 31.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.00, compared to a current price of $6.06 — trading 51.4% above its estimated fair value. The current 14-Day RSI is 31.92 and 30% below the Biotechnology industry median of 45.58. Arcturus Therapeutics Holdings' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current 14-Day RSI is 31.92 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued.
The current stock price of $6.06 is trading 51.4% above its estimated GF Value™ of $4.00.
GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.
Key valuation signals for ARCT:
14-Day RSI: 31.92
GF Value™: $4.00 vs. price of $6.06 (51.4% above fair value)
Industry Position: 30% below the Biotechnology median (#107 of 1425)
No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcturus Therapeutics Holdings Business Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
56GF Score
Get the complete analysis for ARCT
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARCT has been successfully added to your 
